ProQR Therapeutics N.V. is a biotechnology company that specializes in the development and discovery of novel therapeutic medicines. The company boasts an impressive pipeline of products, including AX-0810 for cholestatic diseases, which targets Na-taurocholate cotransporting polypeptide (NTCP), as well as AX-1412 for cardiovascular diseases (CVDs), which targets Beta-1,4-galactosyltransferase 1 (B4GALT1). ProQR Therapeutics N.V. is also developing various other early-stage research programs, such as AX-1005, AX-2911, AX-0601, AX-9115, and AX-2402. Additionally, the company is developing the Axiomer RNA base-editing platform technology. ProQR Therapeutics N.V. has established notable partnerships with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., Leiden University Medical Center, and Eli Lilly and Company. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
ProQR Therapeutics N.V.'s ticker is PRQR
The company's shares trade on the NASDAQ stock exchange
They are based in Leiden, Netherlands
There are 51-200 employees working at ProQR Therapeutics N.V.
It is https://www.proqr.com/
ProQR Therapeutics N.V. is in the Healthcare sector
ProQR Therapeutics N.V. is in the Biotechnology industry
The following five companies are ProQR Therapeutics N.V.'s industry peers: